Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025187 | 0.87 | KDM4E (0.74) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3305186 | 0.86 | KDM4E (0.50) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3303543 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3305331 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3305299 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3298524 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10059728 | 0.79 | KDM4E (0.58) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3306361 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10059341 | 0.79 | KDM4E (0.58) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3305903 | 0.79 | KDM4E (0.58) | ALDH1A1KDM4ECYP1A2HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | claimed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | claimed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | claimed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2296653-B1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010135470-A1 | PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | ALDH1A1 94/4885KDM4E 2408/4885CYP1A2 2127/4885 |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | ALDH1A1 529/4885KDM4E 2117/4885CYP1A2 3249/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ALDH1A1 529/4885KDM4E 2117/4885CYP1A2 3249/4885 |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | ALDH1A1 2054/4885KDM4E 3381/4885CYP1A2 3246/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | ALDH1A1 529/4885KDM4E 2117/4885CYP1A2 3249/4885 |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.